Wayne Balkan

Dr. Wayne Balkan

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2021 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
LBLuiza L. Bagno
Luiza L. Bagno
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
WBWayne Balkan
Wayne Balkan
JHJoshua M. Hare
Joshua M. Hare
Mesenchymal stromal cells (MSCs; AKA mesenchymal stem cells) stimulate healing and reduce inflammation. Promising therapeutic responses are seen in many late-phase clinical trials, but others have ...

30 August 2023 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
DCDiana Clavellina
Diana Clavellina
WBWayne Balkan
Wayne Balkan
JHJoshua M. Hare
Joshua M. Hare
Acute myocardial infarction (AMI) remains a leading cause of death in the United States. The limited regenerative capacity of cardiomyocytes and the restricted contractility of scar tissue after AMI are not addressed by current pharmacologic interventions. Mesenchymal stem/stromal cells (MSCs) have emerged as a promising therapeutic approach due to their low antigenicity, ease of harvesting, and efficacy and safety in preclinical and clinical studies, despite their low survival and engraftment rates. Other stem cell types, such as induced pluripotent stem cells also show promise and optimizing cardiac repair requires integrating these emerging technologies and strategies. This review offers insights into advancing cell-based therapies for AMI, emphasizing meticulously planned trials with a standardized definition of AMI, for a bench-to-bedside approach. We critically evaluate fundamental studies and clinical trials to provide a comprehensive overview of the advances, limitations and prospects for stem cell therapy in AMI. MSCs show undeniable promise for treating AMI, but addressing their low survival and engraftment rates is crucial for clinical success. Integrating emerging technologies and well-designed trials will harness MSC therapy's full potential in AMI management. Collaborative efforts are vital to developing effective stem cell therapies for AMI patients.

19 January 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ARAngela C. Rieger
Angela C. Rieger
LBLuiza L. Bagno
Luiza L. Bagno
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
VFVictoria Florea
Victoria Florea
JRJose Rodriguez
Jose Rodriguez
JHJoshua M. Hare
Joshua M. Hare
Therapies for heart failure with preserved ejection fraction (HFpEF) are lacking. Growth hormone-releasing hormone agonists (GHRH-As) have salutary effects in ischemic and nonischemic heart failure animal models. Accordingly, we hypothesized that GHRH-A treatment ameliorates chronic kidney disease (CKD)-induced HFpEF in a large-animal model. Female Yorkshire pigs (n = 16) underwent 5/6 nephrectomy via renal artery embolization and 12 wk later were randomized to receive daily subcutaneous injections of GHRH-A (MR-409; n = 8; 30 µg/kg) or placebo (n = 8) for 4 to 6 wk. Renal and cardiac structure and function were serially assessed postembolization. Animals with 5/6 nephrectomy exhibited CKD (elevated blood urea nitrogen [BUN] and creatinine) and faithfully recapitulated the hemodynamic features of HFpEF. HFpEF was demonstrated at 12 wk by maintenance of ejection fraction associated with increased left ventricular mass, relative wall thickness, end-diastolic pressure (EDP), end-diastolic pressure/end-diastolic volume (EDP/EDV) ratio, and tau, the time constant of isovolumic diastolic relaxation. After 4 to 6 wk of treatment, the GHRH-A group exhibited normalization of EDP (P = 0.03), reduced EDP/EDV ratio (P = 0.018), and a reduction in myocardial pro-brain natriuretic peptide protein abundance. GHRH-A increased cardiomyocyte [Ca2+] transient amplitude (P = 0.009). Improvement of the diastolic function was also evidenced by increased abundance of titin isoforms and their ratio (P = 0.0022). GHRH-A exerted a beneficial effect on diastolic function in a CKD large-animal model as demonstrated by improving hemodynamic, structural, and molecular characteristics of HFpEF. These findings have important therapeutic implications for the HFpEF syndrome. Significance This randomized, blinded study used rigorous hemodynamic tools to test the efficacy of a synthetic growth hormone-releasing hormone agonist (GHRH‐A) on the restoration of diastolic function in a large animal model of chronic kidney disease (CKD)-induced heart failure with preserved ejection fraction (HFpEF). CKD was produced in Yorkshire swine by performing a 5/6 nephrectomy via catheter-based renal artery embolization. HFpEF was evident at 12 wk postembolization. Daily injection of GHRH-A improved cardiac diastolic hemodynamics, including end-diastolic pressure, end-diastolic pressure–volume ratio, and stroke work, compared to placebo. Development of this swine model and therapeutic approach has important implications because of the high prevalence of CKD-induced HFpEF and cardiorenal syndromes, lack of effective therapies, and few large-animal models available for investigation.

7 January 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
Amarylis Claudine WanschelAmarylis Claudine Wanschel
Amarylis Claudine Wanschel
DGDaniele Guizoni
Daniele Guizoni
ELEstela Lorza-Gil
Estela Lorza-Gil
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
APAdriene A. Paiva
Adriene A. Paiva
HOHelena C. F. Oliveira
Helena C. F. Oliveira
Endothelial dysfunction precedes atherosclerosis and is an independent predictor of cardiovascular events. Cholesterol levels and oxidative stress are key contributors to endothelial damage, whereas high levels of plasma high-density lipoproteins (HDL) could prevent it. Cholesteryl ester transfer protein (CETP) is one of the most potent endogenous negative regulators of HDL-cholesterol. However, whether and to what degree CETP expression impacts endothelial function, and the molecular mechanisms underlying the vascular effects of CETP on endothelial cells, have not been addressed. Acetylcholine-induced endothelium-dependent relaxation of aortic rings was impaired in human CETP-expressing transgenic mice, compared to their non-transgenic littermates. However, endothelial nitric oxide synthase (eNOS) activation was enhanced. The generation of superoxide and hydrogen peroxide was increased in aortas from CETP transgenic mice, while silencing CETP in cultured human aortic endothelial cells effectively decreased oxidative stress promoted by all major sources of ROS: mitochondria and NOX2. The endoplasmic reticulum stress markers, known as GADD153, PERK, and ARF6, and unfolded protein response effectors, were also diminished. Silencing CETP reduced endothelial tumor necrosis factor (TNF) α levels, intercellular cell adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) expression, diminishing monocyte adhesion. These results support the notion that CETP expression negatively impacts endothelial cell function, revealing a new mechanism that might contribute to atherosclerosis.

15 June 2022 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
RDRaul Dulce
Raul Dulce
RKRosemeire M Kanashiro-Takeuchi
Rosemeire M Kanashiro-Takeuchi
LTLauro M Takeuchi
Lauro M Takeuchi
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
Amarylis Claudine WanschelAmarylis Claudine Wanschel
Amarylis Claudine Wanschel
JHJoshua M. Hare
Joshua M. Hare
To test the hypothesis that the activation of the growth hormone-releasing hormone (GHRH) receptor signalling pathway within the myocardium both prevents and reverses diastolic dysfunction and pathophysiologic features consistent with heart failure with preserved ejection fraction (HFpEF). Impaired myocardial relaxation, fibrosis, and ventricular stiffness, among other multi-organ morbidities, characterize the phenotype underlying the HFpEF syndrome. Despite the rapidly increasing prevalence of HFpEF, few effective therapies have emerged. Synthetic agonists of the GHRH receptors reduce myocardial fibrosis, cardiomyocyte hypertrophy, and improve performance in animal models of ischaemic cardiomyopathy, independently of the growth hormone axis. CD1 mice received 4- or 8-week continuous infusion of angiotensin-II (Ang-II) to generate a phenotype with several features consistent with HFpEF. Mice were administered either vehicle or a potent synthetic agonist of GHRH, MR-356 for 4-weeks beginning concurrently or 4-weeks following the initiation of Ang-II infusion. Ang-II-treated animals exhibited diastolic dysfunction, ventricular hypertrophy, interstitial fibrosis, and normal ejection fraction. Cardiomyocytes isolated from these animals exhibited incomplete relaxation, depressed contractile responses, altered myofibrillar protein phosphorylation, and disturbed calcium handling mechanisms (ex vivo). MR-356 both prevented and reversed the development of the pathological phenotype in vivo and ex vivo. Activation of the GHRH receptors increased cAMP and cGMP in cardiomyocytes isolated from control animals but only cAMP in cardiac fibroblasts, suggesting that GHRH-A exert differential effects on cardiomyocytes and fibroblasts. These findings indicate that the GHRH receptor signalling pathway(s) represents a new molecular target to counteract dysfunctional cardiomyocyte relaxation by targeting myofilament phosphorylation and fibrosis. Accordingly, activation of GHRH receptors with potent, synthetic GHRH agonists may provide a novel therapeutic approach to management of the myocardial alterations associated with the HFpEF syndrome. Proposed mechanism of action for GHRH-As to modulate the Excitation-Contraction Coupling (ECC). It is well known that activation of GHRHRs (GPCR) induces the adenylyl cyclase (AC)/cyclic AMP/protein kinase A (PKA) pathway. PKA can both phosphorylate sarcomeric and calcium handling proteins and activate soluble guanylyl cyclase (sGC). This pathway also promotes reparative mechanisms at transcriptional level. On the other hand, has been well demonstrated that GHRH-As also promote activation of AKT (PKB) among other kinases. Endothelial Nitric Oxide Synthase eNOS) is also activated by GHRH. The generated nitric oxide (NO) in turn activates sGC to produce the second messenger cGMP, an activator of the protein kinase G (PKG). This kinase is also able to phosphorylate the above-mentioned proteins. This pathway has been proposed to be activated downstream GHRHRs through activation of PI3K by the Gβγ proteins or β-arrestins (among other possible mechanisms).

8 March 2011 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
WBWayne Balkan
Wayne Balkan
MRMaría Rodríguez-Gonzalez
María Rodríguez-Gonzalez
MPManhui Pang
Manhui Pang
IFIsabel Fernandez
Isabel Fernandez
BTBruce R. Troen
Bruce R. Troen